Newsroom | 6647 results

ÁMSTERDAM--(BUSINESS WIRE)--Avanzanite Bioscience B.V., una empresa farmacéutica europea en fase comercial y en rápido crecimiento que se especializa en las enfermedades raras, ha informado hoy que su socio, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), una empresa biofarmacéutica en fase comercial radicada en Cambridge, Massachusetts, que se dedica a ofrecer medicamentos innovadores para los pacientes con enfermedades raras, ha anunciado que la Comisión Europea le ha otorgado la autorización de...

AMSTERDAM--(BUSINESS WIRE)--Avanzanite Bioscience B.V., een snel groeiende Europees bedrijf in commerciële fase, actief in gespecialiseerde farmaceutica gericht op zeldzame aandoeningen, maakte vandaag bekend dat zijn partner Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), een biofarmaceutisch bedrijf in commerciële fase met hoofdzetel in Cambridge, Massachusetts, dat zich toelegt op het leveren van innovatieve geneesmiddelen voor patiënten met zeldzame aandoeningen, aangekondigd heeft dat de Europ...

AMSTERDAM--(BUSINESS WIRE)--Avanzanite Bioscience B.V., azienda farmaceutica europea specializzata in fase commerciale in rapida crescita, che si concentra sulle malattie rare, ha comunicato oggi che il suo partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), un'azienda biofarmaceutica in fase commerciale con sede a Cambridge, Massachusetts, che si dedica alla distribuzione di medicinali innovativi per pazienti affetti da malattie rare, ha annunciato che la Commissione europea ha rilasciato l'a...

AMSTERDAM--(BUSINESS WIRE)--Avanzanite Bioscience B.V., une société pharmaceutique européenne spécialisée dans les maladies rares, en phase commerciale et en pleine expansion, a fait savoir aujourd’hui que son partenaire, Agios Pharmaceuticals, Inc. (Nasdaq : AGIO), une société biopharmaceutique en phase commerciale dont le siège social est situé à Cambridge, dans le Massachusetts, et qui se consacre à la mise au point de médicaments innovants destinés aux patients atteints de maladies rares, a...

AMSTERDAM--(BUSINESS WIRE)--Avanzanite Bioscience B.V., ein schnell wachsendes europäisches Spezialpharmaunternehmen im kommerziellen Stadium, das sich auf seltene Krankheiten konzentriert, gab heute bekannt, dass sein Partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), ein biopharmazeutisches Unternehmen im kommerziellen Stadium mit Sitz in Cambridge, Massachusetts, das sich auf die Bereitstellung innovativer Medikamente für Patienten mit seltenen Krankheiten konzentriert, mitgeteilt hat, das...

LOS ANGELES--(BUSINESS WIRE)--Faraday Future Intelligent Electric Inc. (NASDAQ: FFAI) (“Faraday Future,” “FF” or the “Company”), a California-based global Embodied AI (EAI) ecosystem company, today announced the results of its 2026 Annual Meeting of Stockholders (the “Annual Meeting”) held today, May 22nd, at which the Company’s stockholders approved all of the submitted proposals, which were meant to enhance FF’s financial stability and empower the leadership team to execute its strategic plan...

INDIANAPOLIS, Ind.--(BUSINESS WIRE)--HealthNet and AndHealth celebrated the ribbon cutting of the newly opened HealthNet Pharmacy this week, marking a major investment in affordable pharmacy access, integrated specialty care, and medication support services for patients across Central Indiana. The new pharmacy is located inside HealthNet Specialty Care at Barrington Health & Dental Center on Indianapolis’ east side and expands the organization’s ability to serve patients facing rising barri...

AMSTERDAM--(BUSINESS WIRE)--Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat)...

NEW YORK--(BUSINESS WIRE)--BBRC International PTE Limited (together with its affiliates, “BBRC” or “we”), a long-term stockholder of Victoria’s Secret & Co. (NYSE: VSCO) (“VS” or the “Company”) and owner of approximately 13% of the Company’s outstanding shares, today issued the following statement in response to the Company’s May 20 presentation. “Over the past year, VS has repeatedly misrepresented BBRC’s intentions while ignoring every concern we have raised regarding the Board’s slow and...

GREENSBORO, N.C.--(BUSINESS WIRE)--Tanger® (NYSE: SKT), a leading owner and operator of outlet and other open-air retail shopping destinations, has released its 2025 Impact Report for the annual period ending December 31, 2025, marking a decade of reporting on the company’s sustainability and corporate responsibility initiatives. Also today, the Institute for Market Transformation announced that Tanger has been named a 2026 Green Lease Leader at the Silver level. Launched in 2014, Green Lease L...